News 2024-09-19
Porton Showcases At CPhI Europe, Meeting Your CDMO Experts In Booth 5C17
CPhI Europe stands as a worldwide event in the pharmaceutical industry, bringing together key players, thought leaders, and businesses from across the globe. The event serves as an unparalleled platform for powerful networking, fostering collaborations, and driving forward the growth and innovation of the pharmaceutical sector.
As one of the world's leading CDMO companies, Porton Pharma Solutions will be attending the event. We will engage face-to-face with industry elites from around the world to gain deep insights into the latest trends and developments in the pharmaceutical industry. Additionally, we will share our extensive industry knowledge and product development experience, jointly exploring product innovation to drive forward industry innovation and high-quality growth.
To better interact with industry peers, we have specially arranged two professional presentation sessions at booth 5C17 on the second day (October 9). Our two technical experts will provide cutting-edge technical insights and industry perspectives. The detailed schedule is as follow:
This event will comprehensively showcase Porton's latest achievements in globalization, technological development, and innovation, providing you with fresh perspectives and new ideas to help you gain a competitive edge in the fierce market. If you are interested in attending our booth activities at CPhI, please plan your schedule in advance to join us for discussions. We sincerely invite you to visit us, to explore industry trends together, and to collectively promote high-quality development in the pharmaceutical industry.
From new drug development and process transfer optimization to commercial manufacturing, Porton is dedicated to attentively listening to customer needs and delivering efficient, precise CDMO solutions. Our expertise spans from small molecules (DS-DP) to tides, biologics, and conjugates. For onsite meeting appointments, please contact business@portonpharma.com.
We look forward to seeing you in Milan and witnessing the bright future of the pharmaceutical industry together!
Others
More
News 2025-03-21
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News 2025-03-19
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
